GSK stock: buy or sell?
October 18th, 2019
GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide.
Should I buy GSK stock?Make a decision about when to buy or sell stocks is one of the hardest parts of being a trader or investor. Trading strategies are meant for helping you in the decision process of what stocks to choose and when is the best time to buy them. At Stocks2.com, we like to use very simple but trusted and powerful trend following trading strategies. Simple things usually work the best.
None of our preferred buy setups matches with GlaxoSmithKline stock situation right now, therefore this is not a suitable entry point.
|New all-time high||No|
|New 52 week high||No|
|Price crossing up 200d MA||No|
|100d MA crossing up 200d MA||No|
Is GlaxoSmithKline stock a buy?
Banks and financial institutions publish stock ratings everyday.At Stocks2.com, we collected 15 ratings published for GSK stock in the last month.
|Date||Analyst / Broker||Previous rating||Current rating|
|2019-9-30||Jefferies Financial Group||n/a||Buy|
|2019-9-27||JPMorgan Chase & Co.||n/a||Neutral|
|2019-9-27||Goldman Sachs Group||n/a||Buy|
|2019-9-20||JPMorgan Chase & Co.||n/a||Neutral|
|2019-9-13||Bank of America||n/a||Neutral|
|2019-8-29||Jefferies Financial Group||n/a||Buy|
GSK stock analysis
GlaxoSmithKline stayed stable a tight 0.14% and closed at $42.53.
Shares of GlaxoSmithKline closed on Oct 18th at $42.53 and stayed stable a tight 0.14%. Since price and SMA200d lines crossed up on June, GSK climbed $4.30 (11.25%). Since last July when SMA50d and SMA100d crossed up, GSK price gained $1.58 per share (3.86%). On Sep/30, GSK hit a new all time high, pushing higher than on Sep 26th tops. Check different trading setups that use ATHs as triggers.
GlaxoSmithKline shares grew 0.83% this week, ending at $42.53.
In a weekly time frame, GlaxoSmithKline stock is drawing an uptrend with rising tops and bottoms. Now trading in between its last bottom and last top, GSK might consolidate in a flat-base, waiting to break out over or down under . Not so far away is the last all-time high GlaxoSmithKline marked late September. Early June GSK price bounced up over the SMA of 40 weeks that acted as support stopping new slides. By mid March, SMA20w and SMA40w crossed up triggering a rise of 7.18%.
GSK stock price history
GSK IPO was on March 28th, 1980 at $0.00 per share1. Since then, GSK stock grew a inf%, with a yearly average of inf%. If you had invested $1,000 in GSK stock in 1980, it would worth $inf today.
1: Adjusted price after possible price splits or reverse-splits.
GSK stock historical price chart
GSK stock reached all-time highs on Sep 30th with a price of $43.22.
GSK stock price targetNobody can reliably foresee how stock prices may evolve in the future. However, financial institutions invest time and resources to provide the most accurated estimations to help investors to make their decisions. The accuracy of these stock price predictions is not very high, and you should not blindly believe and make decisions only based on what this ratings or price target predictions say. For the last month we have not found any price target for GlaxoSmithKline stock by any trusted analyst.
Financials and fundamental analysis
Earnings date and Earnings per ShareOn February, GlaxoSmithKline reported its latest financial data, posting a remarkable gain for the Earnings per Share (EPS) ratio. Experts expected $0.70 per share, but GlaxoSmithKline posted $0.79.
|Quarter||Reporting date||Estimated EPS||Actual EPS||Surprise|
Annual financial resultsIn 2018, GlaxoSmithKline annual revenues inched a slightly good 2.10% to $30,821.00 million dollars from $30,186.00 marked in 2017. In line, its profit margin (compared to sales) rose to 11.75%, that is $3,623.00 million.
|2013||$26,510 M||-||$5,440 M20.5%||-|
|2014||$35,840 M||35.19%||$4,293 M12.0%||-21.08%|
|2015||$23,923 M||-33.25%||$8,422 M35.2%||96.16%|
|2016||$27,889 M||16.58%||$912 M3.3%||-89.17%|
|2017||$30,186 M||8.24%||$1,532 M5.1%||67.98%|
|2018||$30,821 M||2.10%||$3,623 M11.8%||136.49%|
Quarterly financial resultsGlaxoSmithKline posted $8,197.00 million in revenues for 2018-Q4, a 1.30% up compared to previous quarter. Reported quarter income marked $1,215.00 M with a profit margin of 14.82%. Profit margin depreciated a -2.70% compared to previous quarter when profit margin was 17.52%. When comparing sales to same quarter last year, GlaxoSmithKline sales marked a dreadful slide and plunged a -20.59%. Looking back to recent quarterly results, GlaxoSmithKline posted 3 positive quarters in a row.
|2017-Q2||$7,320 M||-||$-180 M-2.5%||-|
|2017-Q3||$10,507 M||43.54%||$1,624 M15.5%||-1,002.02%|
|2017-Q4||$10,323 M||-1.75%||$-738 M-7.1%||-145.44%|
|2018-Q1||$7,222 M||-30.04%||$549 M7.6%||-174.41%|
|2018-Q2||$7,310 M||1.22%||$441 M6.0%||-19.67%|
|2018-Q3||$8,092 M||10.70%||$1,418 M17.5%||221.54%|
|2018-Q4||$8,197 M||1.30%||$1,215 M14.8%||-14.32%|
|2019-Q1||$7,661 M||-6.54%||$830 M10.8%||-31.69%|
GlaxoSmithKline ownershipWhen you are planning to invest in a company, it's worth to overview its ownership structure.
GlaxoSmithKline shares owned by insiders (that is, founders, CEO, CTO, main executives or other management staff) currently counts a 0.01% of all shares.
In case of GlaxoSmithKline stock, 11.00% of its shares are held by institutions (mutual funds, pension funds, big banks and other large financial institutions). Bearish positions for GSK stock account 0.00%, no big difference from last month.
The following table compares ownership indicators for other stocks related to GlaxoSmithKline:
|Market cap||$105.9 B||$114.9 B||$341.4 M||$1.1 B||$216.8 B|
|Total shares||2,490.0 M||2,620.0 M||83.7 M||101.3 M||2,560.0 M|
|Float shares||2,450.0 M||2,610.0 M||58.5 M||53.5 M||2,560.0 M|
|- Institutional holdings (%)||11.0%||19.4%||85.1%||81.3%||78.3%|
|- Insider holdings (%)||0.0%||0.0%||1.2%||32.5%||0.1%|
|Shares in short selling||0.0%||0.0%||0.0%||0.0%||0.0%|
|Friday, October 18th, 2019|
|Day range||$42.37 - $42.64|
|Average true range||$0.52|
|50d mov avg||$41.47|
|100d mov avg||$40.77|
|200d mov avg||$39.92|
GlaxoSmithKline performanceTo better understand GlaxoSmithKline performance you must compare its gains with other related stocks in same sector or industry. For GlaxoSmithKline, the comparison is made against Astrazeneca, Dynavax Technologies, Innoviva, Merck, Novartis, Pfizer, and Teva Pharmaceutical Industries.
GlaxoSmithKline competitorsOne check before trading any stock is to have a look a list of its competitors, in this case for GlaxoSmithKline. We chose 8 companies as GlaxoSmithKline competitors as they are in the same industry or have similar market objectives.
- Astrazeneca (AZN)
- Dynavax Technologies (DVAX)
- Innoviva (INVA)
- Merck (MRK)
- Novartis (NVS)
- Pfizer (PFE)
- Teva Pharmaceutical Industries (TEVA)
Latest GSK stock news
- Seeking AlphaGlaxoSmithKline Looks To Boost Sales Of Zejula Upon Potential FDA Approval In Another IndicationJuly 31, 2019
- Seeking AlphaGlaxoSmithKline And Linerixibat In Cholestasis Pruritus: It Is Worth A LookJuly 3, 2019
- Seeking AlphaWe May Pick Up GlaxoSmithKline At Cheaper PricesJune 10, 2019
- Seeking AlphaGlaxoSmithKline & AstraZeneca, Two Brexit Cancellation Income PlaysApril 29, 2019
- Seeking AlphaGlaxoSmithKline And Merck KGaA Position For The Next Wave In Immuno-OncologyFebruary 11, 2019